Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient...

Chronic lymphocytic leukemia (CLL) treatment attributes can impact patient treatment preferences.

A discrete choice experiment survey was conducted among adults with CLL from the United States (12/2024-02/2025). Treatment attributes, selected via literature review and clinical input, spanned across efficacy, safety, and convenience (continuous vs fixed duration with monitoring/hospitalization requirements). Attributes' relative importance was calculated using conditional logistic regression.

Among 199 patients with CLL, attributes with the highest relative importance were progression-free survival (PFS; 29.5%), impact of headache, atrial fibrillation, and kidney dysfunction on quality of life (QoL; 25.9%, 24.4%, and 10.1%, respectively), followed by treatment convenience (5.4%) and impacts of diarrhea (3.5%) and hypertension (1.1%) on QoL. Patients preferred treatments with longer PFS and less impact of headache, atrial fibrillation, and kidney dysfunction on QoL (p < 0.001). Impacts of diarrhea and hypertension on QoL and treatment convenience had no statistically significant influence on treatment preferences.

PFS, impacts of headache, and atrial fibrillation on QoL were the most important treatment attributes for patients with CLL, whereas treatment convenience did not have a statistically significant impact on patient preferences. CLL treatment discussions should incorporate safety alongside efficacy to support patient-centered care.